ID27504A - Formulasi oral baru - Google Patents

Formulasi oral baru

Info

Publication number
ID27504A
ID27504A IDW20010671A ID20010671A ID27504A ID 27504 A ID27504 A ID 27504A ID W20010671 A IDW20010671 A ID W20010671A ID 20010671 A ID20010671 A ID 20010671A ID 27504 A ID27504 A ID 27504A
Authority
ID
Indonesia
Prior art keywords
oral formulation
new oral
new
rivastigamine
releasing
Prior art date
Application number
IDW20010671A
Other languages
English (en)
Indonesian (id)
Inventor
Jorg Ogorka
Oskar Kalb
Rajen Syah
Satish Chandra Khanna
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27547321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID27504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821299.6A external-priority patent/GB9821299D0/en
Priority claimed from GBGB9821298.8A external-priority patent/GB9821298D0/en
Priority claimed from GBGB9826654.7A external-priority patent/GB9826654D0/en
Priority claimed from GBGB9827624.9A external-priority patent/GB9827624D0/en
Priority claimed from GBGB9907822.2A external-priority patent/GB9907822D0/en
Priority claimed from GBGB9907823.0A external-priority patent/GB9907823D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ID27504A publication Critical patent/ID27504A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IDW20010671A 1998-10-01 1999-10-01 Formulasi oral baru ID27504A (id)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9821299.6A GB9821299D0 (en) 1998-10-01 1998-10-01 Organic compounds
GBGB9821298.8A GB9821298D0 (en) 1998-10-01 1998-10-01 Organic compoundsq
GBGB9826654.7A GB9826654D0 (en) 1998-12-03 1998-12-03 Organic compounds
GBGB9827624.9A GB9827624D0 (en) 1998-12-16 1998-12-16 Organic compounds
GBGB9907822.2A GB9907822D0 (en) 1999-04-06 1999-04-06 Organic compounds
GBGB9907823.0A GB9907823D0 (en) 1999-04-06 1999-04-06 Organic compounds

Publications (1)

Publication Number Publication Date
ID27504A true ID27504A (id) 2001-04-12

Family

ID=27547321

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010671A ID27504A (id) 1998-10-01 1999-10-01 Formulasi oral baru

Country Status (23)

Country Link
US (5) US20010033866A1 (cs)
EP (1) EP1121104B1 (cs)
JP (1) JP4012689B2 (cs)
KR (1) KR100603900B1 (cs)
CN (1) CN1406126A (cs)
AT (1) ATE286725T1 (cs)
AU (1) AU764866B2 (cs)
BR (1) BR9914251A (cs)
CA (1) CA2342340C (cs)
CZ (1) CZ302888B6 (cs)
DE (1) DE69923200T2 (cs)
ES (1) ES2237163T3 (cs)
HK (1) HK1052473A1 (cs)
HU (1) HUP0103883A3 (cs)
ID (1) ID27504A (cs)
IL (2) IL141762A0 (cs)
NO (1) NO331689B1 (cs)
NZ (1) NZ510683A (cs)
PL (1) PL196945B1 (cs)
PT (1) PT1121104E (cs)
SK (1) SK285250B6 (cs)
TR (1) TR200100931T2 (cs)
WO (1) WO2000019985A2 (cs)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200100931T2 (tr) * 1998-10-01 2001-10-22 Novartis Ag Yeni sürekli salınımlı oral formülasyonlar
EP2311441A1 (en) * 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
AU6715600A (en) * 1999-08-26 2001-03-19 Elan Corporation, Plc Pharmaceutical formulations
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
CN1466451B (zh) * 2000-09-29 2010-05-12 索尔瓦药物有限公司 不受离子强度影响的持续释放的医药制剂
JP5023412B2 (ja) * 2001-05-09 2012-09-12 吉澤石灰工業株式会社 ホルムアルデヒド廃液の処理剤
PT1424997E (pt) * 2001-09-14 2008-02-28 Scolr Inc Forma de dosagem de libertação prolongada modulada por aminoácidos
JP2005525299A (ja) * 2001-09-14 2005-08-25 スコラー インコーポレイテッド アミノ酸調節性の長期放出投薬形態
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
ES2327914T3 (es) * 2002-08-07 2009-11-05 Novartis Ag Metodo para pronosticar la sensibilidad al tratamiento con ravastigmina basado en el genotipo apoe de pacintes con demencia.
AU2003100262B4 (en) * 2003-04-07 2003-09-18 Jurox Pty Ltd Stable carprofen composition
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
US20060105036A1 (en) * 2003-05-12 2006-05-18 Stephen Peroutka Threo-dops controlled release formulation
DE60330909D1 (de) * 2003-08-08 2010-02-25 Biovail Lab Int Srl Tablette mit modifizierter freisetzung von bupropion hydrochlorid
WO2006020534A2 (en) * 2004-08-09 2006-02-23 Dr. Reddy's Laboratories Ltd. Stabilized desloratadine composition
EP1909770B1 (en) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
KR20080028361A (ko) * 2005-05-03 2008-03-31 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 퀴닌-함유 제어-방출형 제제
KR100990590B1 (ko) * 2005-09-01 2010-10-29 에자이 알앤드디 매니지먼트 가부시키가이샤 붕해성이 개선된 의약 조성물의 제조 방법
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
GB0606562D0 (en) * 2006-03-31 2006-05-10 Novartis Ag Organic compounds
EP2019679B1 (en) 2006-05-23 2018-06-20 Theracos, Inc. Glucose transport inhibitors and methods of use
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
WO2008122014A1 (en) 2007-04-02 2008-10-09 Theracos, Inc. Benzylic glycoside derivatives and methods of use
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
WO2009022345A1 (en) * 2007-08-14 2009-02-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Phenyl carbamates for the treatment of multiple sclerosis
CA2697349C (en) 2007-08-23 2012-04-24 Theracos, Inc. Benzylbenzene derivatives and methods of use
EP2197454A4 (en) * 2007-09-25 2012-07-04 Idexx Lab Inc PHARMACEUTICAL COMPOSITIONS FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
US20110201597A1 (en) * 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
BRPI0916769A2 (pt) 2008-07-15 2017-09-26 Theracos Inc derivados de benzilbenzeno deuterados e métodos de uso
ME02702B (me) 2008-08-22 2017-10-20 Theracos Sub Llc Postupci za pripremu inhibitora sgl t2
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
CA2773592C (en) 2009-09-18 2018-10-23 Chase Pharmaceuticals Corporation Method and composition for treating alzheimer-type dementia
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
CN101797236B (zh) * 2010-03-23 2012-05-23 西南大学 重酒石酸卡巴拉汀口腔崩解片及其制备方法
US8846909B2 (en) 2010-05-24 2014-09-30 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
KR101762999B1 (ko) 2011-04-18 2017-07-28 에자이 알앤드디 매니지먼트 가부시키가이샤 종양 치료제
CN103648486A (zh) * 2011-05-06 2014-03-19 葛兰素史密斯克莱有限责任公司 缓释对乙酰氨基酚制剂
AU2012256501B2 (en) 2011-05-13 2017-04-06 Eb Ip Hybritabs B.V. Drug delivery system
US8524664B2 (en) 2011-06-02 2013-09-03 Colorado Seminary, Which owns and Operates The Univeristy of Denver Methods of treating overproduction of cortisol using ACTH antagonist peptides
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN104053785A (zh) 2011-11-14 2014-09-17 综合医院公司 为患有抑郁症的受试者选择治疗方案的测定法和方法
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US10485800B2 (en) 2012-11-30 2019-11-26 The University Of Rochester Mixed lineage kinase inhibitors for HIV/AIDS therapies
WO2014098176A1 (ja) 2012-12-21 2014-06-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体のアモルファス及びその製造方法
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TW201540301A (zh) 2013-08-16 2015-11-01 Takeda Gmbh 以ｐｄｅ４抑制劑治療認知損傷
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN103877063A (zh) * 2014-03-24 2014-06-25 张绪伟 一种重酒石酸卡巴拉汀胶囊及其制备方法
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
KR101990951B1 (ko) 2015-04-27 2019-06-20 주식회사 네비팜 리바스티그민 함유 서방출 의약조성물
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
KR20190036370A (ko) 2017-09-27 2019-04-04 서원대학교산학협력단 약물의 서방성 제형을 위한 약물전달체
MX2021001249A (es) 2018-07-30 2021-05-27 Biothea Pharma Inc Sal de malonato de epinefrina cristalina.
CN112546037A (zh) * 2020-12-08 2021-03-26 苏州大学 卡巴拉汀在制备抗辐射药中的应用
CN113398273B (zh) * 2021-05-14 2022-07-19 广西壮族自治区中国科学院广西植物研究所 木聚糖衍生物作为亲水性缓释材料在制备药物缓释片中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
HU201906B (en) 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
GB9701695D0 (en) 1997-01-28 1997-03-19 De Beers Ind Diamond Insert for an abrasive tool
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
CN1158071C (zh) * 1997-05-30 2004-07-21 渗透有限公司 多层渗透装置
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
TR200100931T2 (tr) 1998-10-01 2001-10-22 Novartis Ag Yeni sürekli salınımlı oral formülasyonlar
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders

Also Published As

Publication number Publication date
SK4392001A3 (en) 2002-07-02
IL141762A (en) 2010-06-30
PL196945B1 (pl) 2008-02-29
IL141762A0 (en) 2002-03-10
AU6332199A (en) 2000-04-26
US20050175706A1 (en) 2005-08-11
US20030203025A1 (en) 2003-10-30
CA2342340C (en) 2006-08-29
NZ510683A (en) 2003-09-26
CZ20011155A3 (cs) 2001-08-15
HK1052473A1 (zh) 2003-09-19
HUP0103883A3 (en) 2002-11-28
KR20010073168A (ko) 2001-07-31
KR100603900B1 (ko) 2006-07-25
PT1121104E (pt) 2005-05-31
BR9914251A (pt) 2001-06-19
NO20011471D0 (no) 2001-03-22
HUP0103883A2 (hu) 2002-05-29
CZ302888B6 (cs) 2012-01-11
CA2342340A1 (en) 2000-04-13
WO2000019985A3 (en) 2000-07-20
US20070053982A1 (en) 2007-03-08
NO331689B1 (no) 2012-02-27
US6565883B2 (en) 2003-05-20
EP1121104B1 (en) 2005-01-12
AU764866B2 (en) 2003-09-04
WO2000019985A2 (en) 2000-04-13
EP1121104A2 (en) 2001-08-08
CN1406126A (zh) 2003-03-26
TR200100931T2 (tr) 2001-10-22
PL348734A1 (en) 2002-06-03
US20010033866A1 (en) 2001-10-25
SK285250B6 (sk) 2006-09-07
ATE286725T1 (de) 2005-01-15
NO20011471L (no) 2001-03-22
JP2002526402A (ja) 2002-08-20
JP4012689B2 (ja) 2007-11-21
ES2237163T3 (es) 2005-07-16
DE69923200T2 (de) 2005-12-22
DE69923200D1 (de) 2005-02-17
US20030039692A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
ID27504A (id) Formulasi oral baru
MXPA02003321A (es) Composiciones de liberacion controlada que comprenden nimesulida.
MY129356A (en) Electrospun pharmaceutical compositions
ATE253896T1 (de) Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
BR9810495A (pt) Composição farmacêutica
DE60019334D1 (de) Antivirale arznei
ATE291914T1 (de) Zolmitriptanhaltige arzneizusammensetzungen
SE9700885D0 (sv) New pharmaceutical formulation
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
NO20011217D0 (no) Doseringsform omfattende væskeformulering
DE69927374T2 (de) Entzündungshemmende pharmazeutische formulierungen
DE69917796D1 (de) Decursin-enthaltende pharmazeutische zusammensetzungen
MY128759A (en) Oral controlled release formulations
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
SE0001916D0 (sv) Novel formulation
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
ES2186909T3 (es) Agentes antipaludicos y antibabesiosis y composiciones farmaceuticas que los contienen.
DE60234604D1 (de) Orale dosierungsform enthaltend einen therapeutischen wirkstoff und einen gegenwirdenden wirkstoff
ECSP982436A (es) Composicion